Morgan Stanley initiated coverage of BridgeBio (BBIO) with an Overweight rating and $96 price target The firm says the company is positioned as a leading genetic disease company. BridgeBio has Attruby and a diversified late-stage pipeline, which offers strong growth potential, the analyst tells investors in a research note. Morgan Stanley sees 20% upside in the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma: Emerging Rare Disease Leader With Robust Growth Outlook and Discounted Valuation Supporting Buy Rating
- Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
- Alnylam price target lowered to $351 from $370 at Leerink
- BridgeBio price target raised to $86 from $75 at Leerink
- PayPal downgraded, Roku upgraded: Wall Street’s top analyst calls